YAYASAN PETRONAS COMMITS TO PLANTING 50,000 TREES BY 2021

Global Environment Centre (GEC) as implementation partner to assist in upskilling communities

KUALA LUMPUR, Feb 19 (Bernama) —Yayasan PETRONAS announced today its commitment to plant 50,000 trees as part of its environmental conservation Sentuhan Alam initiative. The project, which involves planting trees and enhancing the management of the trees in 14 sites across 11 states in Malaysia, is estimated to reduce carbon emissions by more than 200 tonnes.

Yayasan PETRONAS Chief Executive Officer Nelly Francis Shariah said: “Yayasan PETRONAS has a long legacy of safeguarding the environment. We aim to better the environment through biodiversity conservation and carbon-neutral programmes, such as rainforest conservation in Imbak Canyon, Sabah; marine biodiversity restoration in the Biodiversity, Environment & Conservation (BEACON) project in Sarawak; mangrove rehabilitation and the establishment of the EcoCare Centre in Kerteh, Terengganu.

“We are also working with the Ecosystem Conservation and Tourism programme of the Setiu Wetlands State Park, Terengganu, to upgrade their facilities and drive programmes to eradicate poverty amongst the local communities that live off the biodiversity of the surrounding areas. These efforts began at our areas of operations and are scaled out nationwide, complementing our larger goals for greater environmental sustainability,” she added.

Yayasan PETRONAS’ appointed implementation partner Global Environment Centre (GEC) will be managing the programme for three years until August 2023. GEC’s duties include identifying and managing the setup of suitable planting grounds, selecting suitable plant species, facilitating community nurseries, site preparation, monitoring and ensuring the sustainable growth of the trees planted.

The majority of sites consists of mangroves and peatland forests, with suitable tree species for mangroves sites such as the Rhizophora Mucronata (Bakau Kurap), Rhizophora Apiculata (Bakau Minyak), Bruguiera spp. and more, while the peatland sites will feature species that include the Melicope Lunu-ankenda (Tenggek Burung), Macaranga Pruinosa (Mahang) and Alstonia spp.

Nelly added: “The planting sites and tree species have been carefully identified to ensure it is ecologically viable and sustainable. Our aim is to guarantee at least 70 per cent survival rate for our trees and an improvement in the livelihoods of local forest-reliant communities.”

Improving the livelihood of communities

Yayasan PETRONAS, through GEC, will be engaging communities in the nearby areas where the tree saplings will be planted, to either start up or expand their nurseries. They will be trained on how to care for and effectively monitor and manage the growth of these trees over a period of three years.

Director of GEC, Faizal Parish said: “In addition to establishing the forest tree nurseries, we will offer community groups extensive training in the proper collection and handling of seeds and wildlings, the preparation and maintenance of the planting sites and more. Through the empowerment and skills transfer, we want to enable them to attain a more sustainable livelihood by generating income from forest management and protection to support their daily lives and those of their family.”

Apart from a source of sustainable livelihood, the community is also expected to benefit in other ways from the rehabilitation of forests. This includes enhanced protection from coastal erosion and increases in fisheries for mangrove projects. For peatland forest projects, surrounding communities will benefit from a reduction in peatland fires and haze, as well as enhanced protection of peatland water sources and non-timber forest products. The rehabilitation efforts in lowland forest sites will offer its surrounding communities new opportunities in recreation and ecotourism, as well as protect their water sources.

“Tree planting and forest protection are among the best climate change solutions. Beyond being a great place to store carbon, forests will also help us better adapt to the consequences of the climate crisis – by protecting coastal areas from erosion, reducing the risk of flooding and providing a habitat for a wide variety of wildlife and other plant species,” added Faizal.

PETRONAS Employees Step In Through Walk4Trees

Yayasan PETRONAS’ initiative folds in a commitment made by PETRONAS and its employees in 2019 through a walking challenge called ‘Walk4Trees’. Through this programme, PETRONAS pledges to plant one tree for every million steps completed by its employees, contributing 20,000 out of the 50,000 trees commitment.

“With 20 billion steps, employees are therefore contributing 20,000 trees out of the total that is being planted through this initiative,” said Nelly.

The collective step count currently stands at 12.4 billion, or equivalent to 12,400 trees – and PETRONAS employees are confident that they will achieve its target by June 2021.

Besides contributing their steps towards the programme, PETRONAS employees will also have an opportunity to volunteer in the tree planting programmes. The programme reflects PETRONAS’ commitment to contribute to the society and environment, aligned with the organisation’s Sustainability Agenda on safeguarding the environment.

In addition to conserving the environment, this project also gives PETRONAS employees a meaningful platform to positively impact their health, improve the climate and deliver positive outcomes for communities in need.

In the spirit of inclusivity, the Challenge is also extended to the public, offering them an opportunity to contribute to environmental conservation for a sustainable future. Members of the public may register for the Challenge and record their steps via the BookDoc application, available on the App Store and Play Store.

Within its environment focus area, Sentuhan Alam, Yayasan PETRONAS aims to improve the environment through biodiversity, conservation and carbon-neutral programmes towards enriching lives for a sustainable future.

http://mrem.bernama.com/viewsm.php?idm=39356

Mori Building, Aman partner for major development in heart of Tokyo

.



KUALA LUMPUR, Feb. 18 — Mori Building Co Ltd, Japan’s leading urban landscape developer, will partner with Aman, the operator of diverse world-class luxury hotels and resorts, in the Toranomon-Azabudai Urban Redevelopment Project.

According to a statement, the project is a massive urban renewal undertaking that will revitalise a large area of central Tokyo when completed in 2023.

The two main outcomes of the partnership will be the branded residence Aman Residences, Tokyo; and luxury hotel Janu Tokyo, Aman’s sister brand, marking the debut of the Janu brand in Japan.

Aman Residences, Tokyo will be located on floors 54–64 of the 330-metre A District Tower, offering 91 hotel-branded residences with exclusive services, including a residents-only Aman Spa (some 1,400 metre square).

Janu Tokyo will make its Japan debut with Janu Tokyo on floors 1–13 in the B-2 District Tower. In addition to approximately 120 luxury rooms, Janu Tokyo will boast Japan’s largest spa (some 3,500 metre square) with spa treatment and fitness centre, among others.

President and Chief Executive Officer of Mori Building, Shingo Tsuji said: “Mori Building is joining hands with Aman to provide a world-leading residential environment and hotel unlike anything ever seen in Tokyo, where people will achieve harmony with nature as well as connect with and inspire others through creativity.

“By realising this new form of ‘urban wellness’, Mori Building will enhance Tokyo’s magnetic power.”

— BERNAMA

TELEHEALTH VENTILATORS WORTH MORE THAN RM2 MILLION TO BE DONATED TO MALAYSIAN HOSPITALS TO TREAT COVID-19 PATIENTS IN INTENSIVE CARE


  • Donation is part of the Billion Breath Project and will benefit thousands of severely affected COVID-19 patients in Southeast and South Asia
  • Alpha ventilator is the world’s first telehealth ventilator that facilitates the remote management of patients with severe breathing difficulties
  • The first five Alpha units were donated today to Hospital Selayang in Selangor, where COVID-19 cases have spiked in recent weeks

SINGAPORE, Feb 17 (Bernama-GLOBE NEWSWIRE) — Advanced MedTech Holdings (AMTH), a global medical technology leader headquartered in Singapore, have announced a donation of up to RM2 million worth of Alpha ventilators to hospitals in Malaysia.

The donation is part of the company’s Billion Breath Project, aiming to support healthcare workers in their fight against COVID-19. The initiative has already donated nearly RM3 million worth of ventilators to hospitals in Indonesia, Myanmar and India. Ventilators worth RM2 million will be donated to Malaysia to support care for patients with severe respiratory distress in the intensive care unit (ICU) wards.

The Alpha ventilator enables a small team of healthcare professionals to monitor and adjust the settings for a large number of ventilated patients remotely via an online dashboard. This reduces the need for caregivers to enter in and out of ICU wards to manually adjust ventilator settings, reducing the risk of infection.

In Malaysia, the ventilators will be sent to hospitals in states where infection and hospitalization rates are high, the first being Hospital Selayang in Selangor.

In July 2020, the Alpha ventilator received provisional authorization to be used as an emergency ventilator by Singapore’s Health Sciences Authority.

Abel Ang, Group Chief Executive of Advanced MedTech, said: “We take breathing for granted until we can no longer breathe. Each person takes about 100 million breaths in their lifetime. The Billion Breath Project was started to help people suffering from severe symptoms of COVID-19 recover their ability to breathe again. The remote accessibility of the Alpha ventilator will empower small healthcare teams to manage a large number of patients and will be central to Malaysia’s fight against the pandemic.”

Datuk Dr Mohamed Alwi Abdul Rahman, HOD Emergency Department and Trauma of Hospital Selayang, said: “Access to ventilators is critical factor in our response to COVID-19, especially as cases continue to rise. We’re grateful for the support offered by Advanced MedTech. The Alpha ventilator will significantly boost our ability to deliver life-saving care to patients in a critical condition.”

The Alpha ventilator was developed by ABM Respiratory Care, a medical device company developing novel integrated airway clearance and ventilation solutions and is manufactured and distributed by Advanced MedTech in Singapore.

In Malaysia, Advanced MedTech has partnered with MEDIWIDE SDN. BHD. to help with distribution of the ventilators.

For more information, please contact:

Thomas Harding / Khushboo Tanna / Maryanne Lee
Spurwing Communications
+65 6751 2021
advanced@spurwingcomms.com
 

About Advanced MedTech Holdings

Advanced MedTech Holdings is a global medical technology leader with a core focus in urology devices and services. Headquartered in Singapore, with operations in US, Germany, Spain, France, Italy, China, Malaysia and Japan, the Company serves millions of patients and physicians in 100 countries worldwide. Advanced MedTech Holdings makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world. Advanced MedTech Holdings is a wholly-owned subsidiary of Temasek. For more information on Advanced MedTech Holdings, please visit https://www.advanced-medtech.com/.

About the Alpha

Weighing 4 kg, with up to three hours of internal battery backup, the portable, touchscreen-based ventilator can be deployed in an ICU, ambulatory or subacute setting for pediatric and adult patients. The device has provisional authorisation from HSA in Singapore for use as an emergency ventilator for COVID-19 patients.  

SOURCE : Advanced MedTech

CENTRIENT PHARMACEUTICALS TO ACQUIRE ASTRAL STERITECH, EXPANDING ITS PRODUCT PORTFOLIO WITH STERILE INJECTABLE ANTIBIOTIC FINISHED DOSAGE FORMS

Rotterdam, the Netherlands, Feb 16 (Bernama-GLOBE NEWSWIRE) —

· Further strengthens Centrient Pharmaceuticals’ position as the global business-to-business industry leader in beta-lactam antibiotics
· Broadens Centrient Pharmaceuticals’ product portfolio with sterile injectable Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin finished dosage forms, able to further meet the needs of customers in these segments and become a preferred partner for customers
· Brings in-house manufacturing capabilities for high-quality sterile antibiotic powder injectable finished dosage forms with two US FDA-approved production lines

Centrient Pharmaceuticals (“Centrient”), the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the signing of an agreement for the acquisition of Astral SteriTech Private Limited (“Astral SteriTech”), a leading international manufacturer specialised in sterile antibiotic injectable finished dosage forms. With the acquisition of Astral SteriTech, Centrient strengthens its position as the global business-to-business industry leader in beta-lactam antibiotics.

The acquisition of Astral SteriTech is an important step on Centrient’s journey to become the leading, diversified and fully integrated partner to generics marketers.

The products offered by Astral SteriTech are sterile injectable finished dosage forms for Semi-Synthetic Cephalosporins and Semi-Synthetic Penicillins. Being close to Centrient’s core products of beta-lactam antibiotics, the acquired product portfolio provides Centrient a diversification opportunity within the attractive growing niche segment of sterile injectable antibiotics.

With the broadened product portfolio, Centrient can further meet the needs of its customers in Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin finished dosage forms and become the preferred partner in these segments.

Astral SteriTech has a US FDA-approved manufacturing site with two manufacturing lines and serves customers in highly regulated markets like the United States and other regions such as South Asia.

The transaction is subject to customary regulatory approvals and closing conditions.

Rex Clements, CEO at Centrient said: “The acquisition of Astral SteriTech is a significant step forward on the journey we at Centrient have undertaken to become the preferred commercial partner to our customers in Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin antibiotics.

By broadening of our product portfolio and adding advanced manufacturing capabilities, we will strengthen the delivery of our value proposition of Quality, Reliability and Sustainability.

These finished dosage forms are critical medicines in healthcare but face increasing risks of supply shortage. At Centrient, we are committed to ensuring a sustainable supply of these products in healthcare, in line with our purpose to improve lives by being at the centre of sustainable and accessible healthcare.”

Dr. Dushyant Patel, Chairman and Managing Director at Astral SteriTech said: “We are proud that with Astral SteriTech’s core competencies and proven strong track record in sterile injectable Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin finished dosage forms, we can contribute to synergize and consolidate Centrient’s antibiotics product portfolio, to support their geographical expansion agenda.

Centrient’s vision and strategies for global success blended with Astral SteriTech’s strong fundamentals in the niche area will not only enhance quality of service to existing clients but will help expand the business horizon.”

For the transaction, Barclays acted as the exclusive financial advisor, and Sidley Austin LLP and Trilegal as legal advisors to Centrient Pharmaceuticals. J.P. Morgan acted as the exclusive financial advisor and Shardul Amarchand Mangaldas & Co as legal advisor to Astral SteriTech.

———————————————————————————————————————————–

About Astral SteriTech Private Limited

Astral SteriTech is a leading international contract manufacturer specialized in sterile antibiotic powder injectable finished dosage forms.

Established as Astral Pharmaceutical Industries in 1991 by Dr. Dushyant Patel, current Chairman and Managing Director, and renamed into Astral SteriTech Private Limited in 2012, the company carved its niche as a preferred Contract and Development Manufacturing Organisation in the industry segment of sterile antibiotic injectable formulations. The company has a US FDA-approved manufacturing site with two dedicated manufacturing lines, located in Vadodara, Gujarat, India, and serves customers in high regulated markets like the United States and other regions such as South Asia.

The company’s core competencies include advanced aseptic fill and finish technologies and processes, the highest quality standards supported by its robust Quality System, regulatory services along all product development stages, and extensive product development knowledge.

For more information on Astral SteriTech please visit www.astralsteritech.com.

About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins and anti-fungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.  

We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2200 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.  

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm. 

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E-Mail: alice.beijersbergen@centrient.com.

Forward-looking statements

This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial

performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.

Alice Beijersbergen
Centrient Pharmaceuticals
+31 (6) 823 579 56
alice.beijersbergen@centrient.com

SOURCE: Centrient Pharmaceuticals

–BERNAMA

Partnerships further accelerate private travel during pandemic – VistaJet research

KUALA LUMPUR, Feb 10 — Strategic industry partnerships — linking businesses across different segments of the luxury travel, hospitality and leisure sector — are widely seen as a key component to further the recovery from the impact caused by the COVID-19 pandemic.

New research from VistaJet, the first and only global business aviation company, in association with Barton, the high-net-worth insight consultants, demonstrates the far-ranging value placed on partnerships by leading businesses in the sector.

While private aviation has continued to see an influx of new customers, according to VistaJet’s report, The Future of Private Travel, the impact of the pandemic in 2020 has in general been severe for many international luxury travel and hospitality businesses, with over three-quarters (77.8 per cent) of businesses having seen net revenue fall by at least 60 per cent year-on-year, and around 43 per cent seeing a drop of over 90 per cent.

Despite a promising vaccine programme, many businesses are still cautious about forecasting a quick recovery in the immediate months ahead. However, 25.9 per cent are optimistic and are starting to refocus their offering onto a HNW target group, predicting a rapid recovery to pre-pandemic levels.

VistaJet itself saw an increase of 29 per cent in new Members joining in 2020, while its sister brand XO has seen new membership sales up 3x.

In a statement, VistaJet Chief Commercial Officer, Ian Moore said: “While the impact of COVID-19 has been significant on a number of luxury travel, hospitality and leisure businesses, it is clear that business aviation is leading this entire sector with a V-shaped recovery.

“Hence, we are increasing the number of partnerships to help accelerate the whole sector’s path to recovery.”

VistaJet is part of Vista Global Holding — the world’s first private aviation ecosystem, integrating a unique portfolio of companies offering asset-light solutions to cover all key aspects of business aviation.

For details, visit vistajet.com

— BERNAMA